Quantcast

OPKO Health has doubled down on their exclusive licensing deal with Arctic Partners Ab Oy (Turku, Finland) for two biomarkers in the kallikrein family which used together with prostate specific antigen, PSA, can reduce the need for prostate biopsies by over 50%. OPKO exercised a right of first refusal to secure additional proprietary information, patents, know-how, property and technology associated with time-resolved fluorescence detection technology, which is directly applicable to the novel prostate cancer biomarkers. OPKO will pursue commercialization of the assay panel on platforms for use in a laboratory setting as well as the point-of-care.

“Kallikrein markers can be assessed on a variety of detection platforms, and the additional technology gained by executing this secondary agreement with Arctic will accelerate our path to market,” said Phillip Frost, M.D., Chairman and CEO of OPKO Health.

Leave a Reply

Your email address will not be published. Required fields are marked *

*